Lymphoma Nonhodgkin Clinical Trial
Official title:
Revlimid® Capsules General Drug Use-results Survey (Relapsed or Refractory Follicular Lymphoma and Marginal Zone Lymphoma)
To ascertain the safety of Revlimid® Capsules 2.5 mg or 5 mg under the actual use conditions in patients who received R2 combination therapy with the drug and rituximab for the first time for relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL). In particular, this surveillance will collect only information of occurrence state and treatment methods on bone marrow depression (neutropenia), which is specified as a safety specification, as well as on tumor flare, for which attention should be called. 1. Planned registration period 1.5 years 2. Planned surveillance period 3 years from the start of this survey
| Status | Recruiting |
| Enrollment | 110 |
| Est. completion date | March 27, 2025 |
| Est. primary completion date | March 27, 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma Exclusion Criteria: - N/A |
| Country | Name | City | State |
|---|---|---|---|
| Japan | Local Institution | Japan |
| Lead Sponsor | Collaborator |
|---|---|
| Celgene |
Japan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Adverse Events (AEs) | Number of participants with adverse events | Up to approximately 3 years |